JP2007537299A5 - - Google Patents

Download PDF

Info

Publication number
JP2007537299A5
JP2007537299A5 JP2007513459A JP2007513459A JP2007537299A5 JP 2007537299 A5 JP2007537299 A5 JP 2007537299A5 JP 2007513459 A JP2007513459 A JP 2007513459A JP 2007513459 A JP2007513459 A JP 2007513459A JP 2007537299 A5 JP2007537299 A5 JP 2007537299A5
Authority
JP
Japan
Prior art keywords
antibody
drug
medicament
medicament according
allograft
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2007513459A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007537299A (ja
JP5161567B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/017048 external-priority patent/WO2005110481A2/en
Publication of JP2007537299A publication Critical patent/JP2007537299A/ja
Publication of JP2007537299A5 publication Critical patent/JP2007537299A5/ja
Application granted granted Critical
Publication of JP5161567B2 publication Critical patent/JP5161567B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2007513459A 2004-05-14 2005-05-16 補体活性を阻害することによる同種移植片の生存の延長 Expired - Lifetime JP5161567B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US57144404P 2004-05-14 2004-05-14
US60/571,444 2004-05-14
PCT/US2005/017048 WO2005110481A2 (en) 2004-05-14 2005-05-16 Prolongation of survival of an allograft by inhibiting complement activity

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012246213A Division JP5590624B2 (ja) 2004-05-14 2012-11-08 補体活性を阻害することによる同種移植片の生存の延長

Publications (3)

Publication Number Publication Date
JP2007537299A JP2007537299A (ja) 2007-12-20
JP2007537299A5 true JP2007537299A5 (enExample) 2008-07-03
JP5161567B2 JP5161567B2 (ja) 2013-03-13

Family

ID=35385551

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2007513459A Expired - Lifetime JP5161567B2 (ja) 2004-05-14 2005-05-16 補体活性を阻害することによる同種移植片の生存の延長
JP2012246213A Expired - Lifetime JP5590624B2 (ja) 2004-05-14 2012-11-08 補体活性を阻害することによる同種移植片の生存の延長
JP2014021907A Withdrawn JP2014080438A (ja) 2004-05-14 2014-02-07 補体活性を阻害することによる同種移植片の生存の延長

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2012246213A Expired - Lifetime JP5590624B2 (ja) 2004-05-14 2012-11-08 補体活性を阻害することによる同種移植片の生存の延長
JP2014021907A Withdrawn JP2014080438A (ja) 2004-05-14 2014-02-07 補体活性を阻害することによる同種移植片の生存の延長

Country Status (14)

Country Link
US (3) US20090028850A1 (enExample)
EP (4) EP3056218A1 (enExample)
JP (3) JP5161567B2 (enExample)
AU (1) AU2005244012C1 (enExample)
CA (1) CA2566716C (enExample)
DK (1) DK1755674T3 (enExample)
ES (1) ES2528362T3 (enExample)
HK (2) HK1222342A1 (enExample)
IL (2) IL179240A (enExample)
NZ (1) NZ551308A (enExample)
PL (1) PL1755674T3 (enExample)
PT (1) PT1755674E (enExample)
SI (1) SI1755674T1 (enExample)
WO (1) WO2005110481A2 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3056218A1 (en) 2004-05-14 2016-08-17 Alexion Pharmaceuticals, Inc. Prolongation of survival of an allograft by inhibiting complement activity
EP1988882B1 (en) * 2006-03-02 2014-12-17 Alexion Pharmaceuticals, Inc. Prolongation of survival of an allograft by inhibiting complement activity
DK2359834T5 (en) * 2006-03-15 2017-02-06 Alexion Pharma Inc Treatment of paroxysmal nocturnal hemoglobinuria patients with a complement inhibitor
EP3028716B1 (en) 2006-10-10 2020-09-16 Regenesance B.V. Complement inhibition for improved nerve regeneration
RS64039B1 (sr) * 2008-11-10 2023-04-28 Alexion Pharma Inc Metode i kompozicije za lečenje poremećaja povezanih sa komplementom
US20110110953A1 (en) * 2009-06-29 2011-05-12 Dennis Keith Bishop Compound and method for treatment of chronic transplant rejection
AU2010266127B2 (en) * 2009-07-02 2015-11-05 Musc Foundation For Research Development Methods of stimulating liver regeneration
US9420770B2 (en) 2009-12-01 2016-08-23 Indiana University Research & Technology Corporation Methods of modulating thrombocytopenia and modified transgenic pigs
US9527912B2 (en) 2010-05-17 2016-12-27 The Board Of Trustees Of The Leland Stanford Junior University Prevention of immunological rejection of transplanted stem cells by leukocyte costimulatory molecule blockade
PL2884999T3 (pl) 2012-08-20 2021-07-05 Fred Hutchinson Cancer Research Center Sposób i kompozycje do immunoterapii komórkowej
AU2014306002B2 (en) 2013-08-07 2017-05-25 Alexion Pharmaceuticals, Inc. Atypical hemolytic uremic syndrome (aHUS) biomarker proteins
EP3033093A1 (en) 2013-08-16 2016-06-22 Alexion Pharmaceuticals, Inc. Treatment of graft rejection by administering a complement inhibitor to an organ prior to transplant
JP6479974B2 (ja) 2014-10-15 2019-03-06 アレクシオン ファーマシューティカルズ， インコーポレイテッド 大規模エクリズマブ産生細胞培養を再現する方法
US20180311299A1 (en) * 2015-05-01 2018-11-01 Alexion Pharmaceuticals, Inc. Efficacy of an anti-c5 antibody in the prevention of antibody mediated rejection in sensitized recipients of a kidney transplant
MY191668A (en) 2016-06-14 2022-07-06 Regeneron Pharma Anti-c5 antibodies and uses thereof
JP2021506241A (ja) 2017-12-13 2021-02-22 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 抗ｃ５抗体組み合わせ物およびその使用
US20190247560A1 (en) 2018-02-13 2019-08-15 Gambro Lundia Ab Extracorporeal devices and methods of treating complement factor related diseases
GB201911931D0 (en) * 2019-08-20 2019-10-02 Univ College Cardiff Consultants Ltd Anti-C7 antibody or antibody fragment
US20210353685A1 (en) * 2020-05-14 2021-11-18 Brain Cancer Research Institute Augmentation of Cell Therapy Efficacy by Inhibition of Complement Activation Pathways
CN114532982A (zh) * 2022-01-12 2022-05-27 高谋 评价干细胞系统移植调控补体活化作用的体系
CN120344253A (zh) * 2022-12-08 2025-07-18 诺麦塔制药有限公司 延长移植物和受体存活期的组合物和方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2588579B2 (ja) 1988-04-21 1997-03-05 株式会社クラレ 耐熱水性にすぐれたポリビニルアルコール系繊維およびその製造法
US5573940A (en) 1989-06-12 1996-11-12 Oklahoma Medical Research Foundation Cells expressing high levels of CD59
US5135916A (en) * 1989-06-12 1992-08-04 Oklahoma Medical Research Foundation Inhibition of complement mediated inflammatory response
US5705732A (en) * 1989-06-12 1998-01-06 Oklahoma Medical Research Foundation Universal donor cells
US20010018051A1 (en) * 1990-04-09 2001-08-30 White David James Graham Inhibition of allograft and concordant xenograft rejection
GB9007971D0 (en) * 1990-04-09 1990-06-06 Imutran Ltd Pharmaceutical formulations
EP0560929A1 (en) 1990-12-06 1993-09-22 T Cell Sciences, Inc. Synergistic compositions of soluble complement receptors and compounds that inhibit complement and/or suppress immune activity
US5456909A (en) * 1992-08-07 1995-10-10 T Cell Sciences, Inc. Glycoform fractions of recombinant soluble complement receptor 1 (sCR1) having extended half-lives in vivo
US5308341A (en) 1993-09-28 1994-05-03 Becton, Dickinson And Company Method of testing the dose accuracy of a medication delivery device
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
US5679345A (en) * 1994-06-02 1997-10-21 The Johns Hopkins University Method for preventing complement-dependent rejection of organ or tissue transplants
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6355242B1 (en) * 1997-05-23 2002-03-12 Ixion Biotechnology, Inc. Materials and methods for treating or preventing oxalate-related disease
ATE265220T1 (de) 1998-02-04 2004-05-15 Gen Hospital Corp Kostimulatorische blockade und gemischter chimerismus in allotransplantationen
US6302855B1 (en) * 1998-05-20 2001-10-16 Novo Nordisk A/S Medical apparatus for use by a patient for medical self treatment of diabetes
WO2000027421A2 (en) 1998-11-06 2000-05-18 The Schepens Eye Research Institute, Inc. LOCAL USE OF SOLUBLE TUMOR NECROSIS RECEPTOR I (sTNFRI) FOR PROPHYLAXIS AND TREATMENT OF CORNEAL TRANSPLANT REJECTION AND OTHER DISORDERS OF THE EYE
US6192891B1 (en) 1999-04-26 2001-02-27 Becton Dickinson And Company Integrated system including medication delivery pen, blood monitoring device, and lancer
AUPQ431299A0 (en) 1999-11-26 1999-12-23 Unisearch Limited Method of inducing immune tolerance
US6538028B1 (en) * 2000-02-01 2003-03-25 Vanderbilt University Method for inhibiting complement activation
AU2001296594A1 (en) * 2000-10-10 2002-04-22 Tanox, Inc. Inhibition of complement c5 activation for the treatment and prevention of delayed xenograft or acute vascular rejection
PL364359A1 (en) * 2001-06-08 2004-12-13 Novartis Ag Treatment or prophylaxis of insulin-producing cell graft rejection
US7432356B2 (en) 2001-08-17 2008-10-07 Genentech, Inc. Complement pathway inhibitors binding to C5 and C5a without preventing formation of C5b
EP1478354A4 (en) 2002-01-22 2008-09-24 Genzyme Corp USE OF TGF-BETA ANTAGONISTS IN THE TREATMENT OR PREVENTION OF CHRONIC RELEASE OF TRANSPLANT
US7923010B2 (en) * 2003-09-11 2011-04-12 The Board Of Regents Of The University Of Texas System Methods and materials for treating autoimmune diseases and conditions
US20050169921A1 (en) * 2004-02-03 2005-08-04 Leonard Bell Method of treating hemolytic disease
EP3056218A1 (en) 2004-05-14 2016-08-17 Alexion Pharmaceuticals, Inc. Prolongation of survival of an allograft by inhibiting complement activity
CA2566861A1 (en) * 2004-05-17 2005-12-08 Combinatorx, Incorporated Methods and reagents for the treatment of immunoinflammatory disorders

Similar Documents

Publication Publication Date Title
JP2007537299A5 (enExample)
JP2009528369A5 (enExample)
RU2008139118A (ru) Продление срока выживаемости аллотрансплантата путем ингибирования активности комплемента
JP5590624B2 (ja) 補体活性を阻害することによる同種移植片の生存の延長
de Fijter The impact of age on rejection in kidney transplantation
EP1567138B1 (en) Use of a diamide derivative for inhibiting chronic transplant rejection
Kann et al. Past, present, and future research in the field of composite tissue allotransplantation
JP2002530354A5 (enExample)
Starzl The French heritage in clinical kidney transplantation
JP2006514015A5 (enExample)
WO2019159731A1 (ja) 慢性移植肺機能不全の改善又は予防薬
US20240197816A1 (en) Composition and method for prolong survival of transplant and recipient
Dean et al. The immunosuppression of pigs: a review
Starzl et al. The enigma of graft acceptance
Inoue et al. Cyclosporine and partial liver allotransplants in a simplified rat model
Wang Strategies for Prevention of Antibody Mediated Allograft Rejection
Allografts Immunomodulation of the Composite Tissue Allograft
JP2007153829A (ja) 肝細胞再生促進剤、アラニンアミノトランスフェラーゼ低下剤及びアスパラギン酸アミノトランスフェラーゼ低下剤
JPWO2020096371A5 (enExample)
THOMSON et al. Influence of Cyclosporin A
Sharma et al. A Review on Pharmacology of Tacrolimus In Renal Transplant Patients
Vincenti et al. NEPHROLOGY–TRANSPLANTATION
Hiotis Donor specific tolerance to rat hindlimb allografts with mixed cell chimerism
AU2011236106A1 (en) Prolongation of survival of an allograft by inhibiting complement activity